Synairgen PLC - respiratory drug discovery company - Says recruitment of 120 Covid-19 patients into its phase II trial evaluating inhaled formulation of interferon-beta-1a conducted in the home setting has now been completed. Results from the trial are expected in the second quarter of 2021. "The trial is both a test of the drug, and a test of how technology can be utilised to deliver and manage the administration of an inhaled broad-spectrum antiviral to vulnerable patients in the context of a pandemic, reducing the need to transport infected patients, and eliminating virus exposure to healthcare workers," explains Chief Executive Richard Marsden.
Current stock price: 162.00 pence, down 5.3% on Wednesday
Year-to-date change: up 5.9%
By Evelina Grecenko; evelinagrecenko@alliancenews.com
Copyright 2021 Alliance News Limited. All Rights Reserved.
Synairgen (SNG)